Furthermore, Kendsersky et al. have demonstrated in vivo efficacy of the B7-H3-targeting antibody–drug conjugate (ADC) m276-SL-PBD in patient-derived xenograft (PDX) models of neuroblastoma [141]. This evidence concerns the gene CD276 and neuroblastoma.